Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Education and awareness of rare and ultra rare diseases, patient access to orphan drugs, and newborn screening modernization and reauthorization.
Advocating for increased funding for HHS grant programs related to state newborn screening programs.
Duration: May 1, 2021
to
February 29, 2024
General Issues: Medicare/Medicaid , Health Issues , Budget/Appropriations
Spending: about $750,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2021: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
THE MCMANUS GROUP terminated an engagement in which they represented Orchard Therapeutics North America on April 22.
Original Filing: 301575946.xml
Lobbying Issues
Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases, patient access to orphan drugs, and newborn screening modernization and reauthorization.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Advocating for increased funding for HHS grant programs related to state newborn screening programs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2023
In Q4, THE MCMANUS GROUP lobbied for Orchard Therapeutics North America , earning $60,000. The report was filed on Jan. 20.
Original Filing: 301534003.xml
Lobbying Issues
Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases, patient access to orphan drugs, and newborn screening modernization and reauthorization.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Advocating for increased funding for HHS grant programs related to state newborn screening programs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2023
In Q3, THE MCMANUS GROUP lobbied for Orchard Therapeutics North America , earning $60,000. The report was filed on Oct. 20, 2023.
Original Filing: 301516573.xml
Lobbying Issues
Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases, patient access to orphan drugs, and newborn screening modernization and reauthorization.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Advocating for increased funding for HHS grant programs related to state newborn screening programs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2023
In Q2, THE MCMANUS GROUP lobbied for Orchard Therapeutics North America , earning $60,000. The report was filed on July 20, 2023.
Original Filing: 301490382.xml
Lobbying Issues
Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases, patient access to orphan drugs, and newborn screening modernization and reauthorization.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Advocating for increased funding for HHS grant programs related to state newborn screening programs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2023
In Q1, THE MCMANUS GROUP lobbied for Orchard Therapeutics North America , earning $80,000. The report was filed on April 20, 2023.
Original Filing: 301466858.xml
Lobbying Issues
Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases, patient access to orphan drugs, and newborn screening modernization and reauthorization including in Newborn Screening Saves Lives Reauthorization Act of 2021.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Advocating for increased funding for HHS grant programs related to state newborn screening programs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2022
In Q4, THE MCMANUS GROUP lobbied for Orchard Therapeutics North America , earning $80,000. The report was filed on Jan. 20, 2023.
Original Filing: 301438524.xml
Lobbying Issues
Access and coverage of inpatient drugs in Medicaid program (H.R.7389 - MVP Act)
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases, patient access to orphan drugs, and newborn screening modernization and reauthorization.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2022
In Q3, THE MCMANUS GROUP lobbied for Orchard Therapeutics North America , earning $80,000. The report was filed on Oct. 20, 2022.
Original Filing: 301415324.xml
Lobbying Issues
Access and coverage of inpatient drugs in Medicaid program (H.R.7389 - MVP Act)
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases, patient access to orphan drugs, and newborn screening modernization and reauthorization.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2022
In Q2, THE MCMANUS GROUP lobbied for Orchard Therapeutics North America , earning $60,000. The report was filed on July 20, 2022.
Original Filing: 301390393.xml
Lobbying Issues
Access and coverage of inpatient drugs in Medicaid program.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases, patient access to orphan drugs, and newborn screening modernization and reauthorization.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2022
In Q1, THE MCMANUS GROUP lobbied for Orchard Therapeutics North America , earning $60,000. The report was filed on April 20, 2022.
Original Filing: 301365363.xml
Lobbying Issues
Access and coverage of inpatient drugs in Medicaid program.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases, patient access to orphan drugs, and newborn screening modernization and reauthorization.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2021
In Q4, THE MCMANUS GROUP lobbied for Orchard Therapeutics North America , earning $100,000. The report was filed on Jan. 20, 2022.
Original Filing: 301336276.xml
Lobbying Issues
Access and coverage of inpatient drugs in Medicaid program.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases, patient access to orphan drugs, and newborn screening modernization.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2021
In Q3, THE MCMANUS GROUP lobbied for Orchard Therapeutics North America , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301311812.xml
Lobbying Issues
Access and coverage of inpatient drugs in Medicaid program.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2021
In Q2, THE MCMANUS GROUP lobbied for Orchard Therapeutics North America , earning $20,000. The report was filed on July 20, 2021.
Original Filing: 301284889.xml
Lobbying Issues
Access and coverage of pharmaceuticals in Medicaid program.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate